Patent · US Active

Modified urokinase-type plasminogen activator polypeptides and methods of use

US11613744B2 · kind B2 · utility

0Cited by

60References

77Claims

0Family size

Assignee

Vertex Pharmaceuticals Incorporated · US

Inventors

Edwin L. Madison · Dallas, US
Christopher D. Thanos · Tiburon, US
Vanessa Soros · South San Francisco, US
Mikhail Popkov · San Diego, US
Kimberly Ann Tipton · San Francisco, US
Matthew John Traylor · Boulder, US
Eric Furfine · Concord, US
Jeffrey Charles Way · Cambridge, US

Key dates

Filing date	Jan 3, 2020
Grant date	Mar 28, 2023
Priority date	—
Expiry date	Oct 24, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.